Department of Forensic Medicine and Molecular Pathology, School of Medicine, Kyoto University, Kyoto 606-8315, Japan.
J Neuroinflammation. 2012 Nov 23;9:256. doi: 10.1186/1742-2094-9-256.
The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is considered to be a potential therapeutic agent for prevention of cerebral ischemia. Ischemia is a most common cause of death after heart attack and cancer causing major negative social and economic consequences. This study was designed to investigate the effect of PACAP38 injection intracerebroventrically in a mouse model of permanent middle cerebral artery occlusion (PMCAO) along with corresponding SHAM control that used 0.9% saline injection.
Ischemic and non-ischemic brain tissues were sampled at 6 and 24 hours post-treatment. Following behavioral analyses to confirm whether the ischemia has occurred, we investigated the genome-wide changes in gene and protein expression using DNA microarray chip (4x44K, Agilent) and two-dimensional gel electrophoresis (2-DGE) coupled with matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS), respectively. Western blotting and immunofluorescent staining were also used to further examine the identified protein factor.
Our results revealed numerous changes in the transcriptome of ischemic hemisphere (ipsilateral) treated with PACAP38 compared to the saline-injected SHAM control hemisphere (contralateral). Previously known (such as the interleukin family) and novel (Gabra6, Crtam) genes were identified under PACAP influence. In parallel, 2-DGE analysis revealed a highly expressed protein spot in the ischemic hemisphere that was identified as dihydropyrimidinase-related protein 2 (DPYL2). The DPYL2, also known as Crmp2, is a marker for the axonal growth and nerve development. Interestingly, PACAP treatment slightly increased its abundance (by 2-DGE and immunostaining) at 6 h but not at 24 h in the ischemic hemisphere, suggesting PACAP activates neuronal defense mechanism early on.
This study provides a detailed inventory of PACAP influenced gene expressions and protein targets in mice ischemic brain, and suggests new targets for thereaupetic interventions.
神经肽垂体腺苷酸环化酶激活肽(PACAP)被认为是预防脑缺血的潜在治疗药物。缺血是心脏病发作和癌症后导致主要负面社会和经济后果的最常见死亡原因。本研究旨在研究 PACAP38 注射对永久性大脑中动脉闭塞(PMCAO)小鼠模型的影响,并与使用 0.9%生理盐水注射的相应 SHAM 对照进行比较。
在治疗后 6 小时和 24 小时采集缺血和非缺血脑组织样本。在进行行为分析以确认是否发生缺血后,我们分别使用 DNA 微阵列芯片(4x44K,Agilent)和二维凝胶电泳(2-DGE)与基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS)相结合,研究基因和蛋白质表达的全基因组变化。还使用 Western 印迹和免疫荧光染色进一步检查鉴定出的蛋白质因子。
我们的结果显示,与生理盐水注射的 SHAM 对照半球(对侧)相比,PACAP38 处理的缺血半球(同侧)的转录组发生了许多变化。在 PACAP 的影响下,鉴定出了先前已知(如白细胞介素家族)和新的(Gabra6、Crtam)基因。同时,2-DGE 分析显示缺血半球中一个高度表达的蛋白质斑点,被鉴定为二氢嘧啶酶相关蛋白 2(DPYL2)。DPYL2 也称为 Crmp2,是轴突生长和神经发育的标志物。有趣的是,PACAP 治疗在 6 小时时略微增加了缺血半球中 DPYL2 的丰度(通过 2-DGE 和免疫染色),但在 24 小时时没有增加,这表明 PACAP 早期激活了神经元防御机制。
本研究提供了 PACAP 影响小鼠缺血性脑内基因表达和蛋白质靶标的详细清单,并为治疗干预提供了新的靶点。